<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02309424</url>
  </required_header>
  <id_info>
    <org_study_id>167/11-06-08</org_study_id>
    <nct_id>NCT02309424</nct_id>
  </id_info>
  <brief_title>The Effect of Vinegar on Glucose and Lipid Metabolism in Subjects With Impaired Glucose Tolerance or Type 2 Diabetes</brief_title>
  <official_title>The Effect of Vinegar on Glucose and Lipid Metabolism in Peripheral Tissues in Subjects With Impaired Glucose Tolerance or Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Attikon Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hellenic National Diabetes Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Attikon Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This open, randomized, cross-over, placebo-controlled study aims to investigate the effects
      of vinegar on glucose metabolism, endothelial function and circulating lipid levels in
      subjects with impaired glucose tolerance or type 2 diabetes, using the arteriovenous
      difference technique.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects with IGT or type 2 diabetes will be randomised to consume 20ml vinegar (6% acetic
      acid) or placebo before a mixed meal. Plasma samples will be taken for 300min from the radial
      artery and from a forearm vein for measurements of glucose, insulin, triglycerides,
      non-esterified fatty acids (NEFA) and glycerol. Muscle blood flow will be measured with
      strain-gauge plethysmography. Glucose flux will be calculated as the arteriovenous difference
      of glucose multiplied by the blood flow rates.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2008</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Muscle glucose uptake following meal ingestion (area under the glucose uptake versus time curve-AUC)</measure>
    <time_frame>0, 30, 60, 90, 120, 180, 240, 300 min postmeal</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma glucose levels following meal ingestion (area under the plasma concentration versus time curve-AUC)</measure>
    <time_frame>0, 30, 60, 90, 120, 180, 240, 300 min postmeal</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma insulin levels following meal ingestion (area under the plasma concentration versus time curve-AUC)</measure>
    <time_frame>0, 30, 60, 90, 120, 180, 240, 300 min postmeal</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma triglyceride levels following meal ingestion (area under the plasma concentration versus time curve-AUC)</measure>
    <time_frame>0, 30, 60, 90, 120, 180, 240, 300 min postmeal</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma NEFA levels following meal ingestion (area under the plasma concentration versus time curve-AUC)</measure>
    <time_frame>0, 30, 60, 90, 120, 180, 240, 300 min postmeal</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma glycerol levels following meal ingestion (area under the plasma concentration versus time curve-AUC)</measure>
    <time_frame>0, 30, 60, 90, 120, 180, 240, 300 min postmeal</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Muscle blood flow following meal ingestion (area under the blood flow rates versus time curve-AUC)</measure>
    <time_frame>0, 30, 60, 90, 120, 180, 240, 300 min postmeal</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with adverse events</measure>
    <time_frame>300 min postmeal</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>Vinegar</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>0,50mmol vinegar (6% acetic acid)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>50 ml water</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Vinegar</intervention_name>
    <description>0,50mmol vinegar (6% acetic acid)</description>
    <arm_group_label>Vinegar</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>50 ml water</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subjects with impaired glucose tolerance or newly diagnosed type 2 diabetes before the
             initiation of medication therapy

          2. Recreationally active

          3. With stable body weight and diet during the last two months.

        Exclusion Criteria:

          1. Any systemic disease (besides glucose abnormalities)

          2. Any medication therapy

          3. Diabetic complications
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>George D Dimitriadis, Professor</last_name>
    <role>Study Director</role>
    <affiliation>Attikon Hospital</affiliation>
  </overall_official>
  <verification_date>December 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 1, 2014</study_first_submitted>
  <study_first_submitted_qc>December 4, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 5, 2014</study_first_posted>
  <last_update_submitted>December 4, 2014</last_update_submitted>
  <last_update_submitted_qc>December 4, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 5, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Attikon Hospital</investigator_affiliation>
    <investigator_full_name>Panayota Mitrou</investigator_full_name>
    <investigator_title>Senior Researcher, MD, PhD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Glucose Intolerance</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

